Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: WhatsUpWithThat who wrote (9233)	9/30/2003 6:36:26 PM
From: Icebrg	Read Replies (1) \| Respond to of 52153

>>Am I missing something?>> Not necessarily. It was a very interesting piece of reporting. Either Reuter's reporter was totally confused or the company and Mr Kaplan were. My bet is on the journalist. I liked this statement very much. "There are no side-effects apart from the side-effects", so to say. Erik Phensarine's binding action does not cause side effects, but blockage of the acetylcholinesterase enzyme causes nausea and vomiting at rates similar to those seen with other drugs in the same class. Phensarine is more likely to cause dizziness than the other drugs, because it is powered to get into the brain, Hausman said, adding that Axonyx is working to fine-tune the dose.